fludrocortisone


Also found in: Dictionary, Wikipedia.
Related to fludrocortisone: Midodrine, fludrocortisone acetate

fludrocortisone

 [floo″dro-kor´tĭ-sōn]
a synthetic steroid with potent mineralocorticoid and high glucocorticoid activity, used as the acetate salt in replacement therapy for primary or secondary adrenocortical insufficiency in addison's disease and for the treatment of salt-losing syndrome and adrenogenital syndrome.

fludrocortisone

(flo͞o′drō-kôr′tĭ-sōn′, -zōn′)
n.
A synthetic steroid used therapeutically to increase blood pressure by lowering the amount of salt the body excretes.

fludrocortisone

Endocrinology A synthetic steroid used to replace steroids normally produced by the adrenal gland, when the gland is structurally or functionally compromised

fludrocortisone

A steroid drug with a minor anti-inflammatory action but with a powerful sodium-retaining effect, similar to that of ALDOSTERONE. It is thus useful in the treatment of ADDISON'S DISEASE, to replace aldosterone. The drug is on the WHO official list. A brand name is Florinef.
References in periodicals archive ?
- Fludrocortisone - Market size and forecast 2018-2023
As no improvement was seen with the sodium deficit treatment, replacement fludrocortisone (2x0.1 mg) was initiated on the 8th day of hyponatremia and on the 7th day of sodium deficit treatment replacement.
In newborns referred with salt wasting crisis, replacement treatment with fludrocortisone and hydrocortisone may be given until differential diagnosis from congenital adrenal hyperplasia is made.1 When patient 2 and 3 were referred with salt wasting, they initially underwent hydrocortisone and fludrocortisone treatment until the hormone tests results were obtained.
He was diagnosed to have primary adrenal insufficiency managed with hydrocortisone and fludrocortisone orally.
Fludrocortisone was started due to hyponatremia and very high urine Na loss despite high Na supplementation at the age of 20 days.
Fludrocortisone, a synthetic mineralocorticoid, is an aldosterone receptor agonist.
[41,42] The multicentre placebo controlled APROCCHSS (Activated Protein C and Corticosteroids for Human Septic Shock) trial randomised 1 241 patients with septic shock to receive corticosteroids (50 mg hydrocortisone bolus every 6 hours intravenously, 50 [micro]g fludrocortisone enterally daily) and/or activated drotrecogin alpha together with their respective placebos.
46XX karyotype, hypoplastic uterus on CT scan and elevated ACTH and 17-hydroxyprogesterone levels lead to the diagnosis of female pseudohermaphroditism due to congenital adrenal hyperplasia and patient was started on glucocorticoids and fludrocortisone by endocrinologist and was also referred to plastic surgeon.
The mean duration of hyponatremia during the study period was 38 hours, and in terms of the specific-pharmacological treatment for these syndromes, only 1 patient was given fludrocortisone, whereas no patient was treated with vasopressin receptor antagonists during the study period.
On the postoperative fourth day, hydrocortisone treatment was replaced by oral maintenance dose (10 mg/m2/day), and fludrocortisone (0.1 mg/day) was added.
Furthermore, registration priority has been given to life saving medicines like Fludrocortisone, D-Pencillamine, Hydrochlorothiazide and Nitrofurontion.